Gerber Tonia, Zeller Andreas
Universitäres Zentrum für Hausarztmedizin beider Basel (uniham-bb), Liestal.
Praxis (Bern 1994). 2021;110(4):193-200. doi: 10.1024/1661-8157/a003623.
Evidence-Based Indication for Proton Pump Inhibitors - a Group Practice Perspective Little is known about the extent of non-evidence-based proton pump inhibitor (PPI) prescriptions in the general practice setting in Switzerland. A recommendation for long-term therapy was included in the "Top 5 list" of "smarter medicine" for the outpatient internal medicine in 2014. The observational study recorded the proportion of patients without evidence-based indication for PPI in a practice with six general practitioners retrospectively over three months. Of 2225 patients analysed, 11.1 % (n = 248) took a PPI. The percentage of patients without a clear evidence-based indication was 46.8 %. Almost every second patient did not have a clear evidence-based indication for PPI. The results could be an incentive for general practitioners to reconsider the indication when prescribing PPI, also in the sense of "smarter medicine".
质子泵抑制剂的循证用药指征——团体医疗视角 在瑞士的普通医疗环境中,对于非循证使用质子泵抑制剂(PPI)的程度了解甚少。2014年,长期治疗的推荐被列入门诊内科“更明智用药”的“五大清单”中。该观察性研究回顾性记录了一家有六位全科医生的诊所中,连续三个月无PPI循证用药指征的患者比例。在分析的2225例患者中,11.1%(n = 248)服用了PPI。无明确循证用药指征的患者比例为46.8%。几乎每两位患者中就有一位没有PPI的明确循证用药指征。这些结果可能会促使全科医生在开具PPI处方时重新考虑用药指征,这也是“更明智用药”的意义所在。